Code | CSB-MP006254HU(F1) |
Size | $570 |
Order now | |
Image |
|
Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant human CXCR4 virus-like particle (VLP) is a nanodimensional structure built from viral structural constituents in the form of recombinant proteins synthesized in mammalian cells. Its expression region encodes the full-length human CXCR4 protein (1-352aa). It carries a 10xHis-tag at the C-terminus. Its endotoxin level is less than 1.0 EU/ug measured by the LAL method. It has been validated to be biologically active. In the functional ELISA, this recombinant human CXCR4 VLP can bind to the anti-CXCR4 recombinant antibody, with the EC50 of 101.7-253.6 ng/mL.
CXCR4 is a pleiotropic chemokine receptor that regulates a variety of physiological processes through its ligand CXCL12, including immune response, hematopoiesis, developmental processes, and pro-tumorigenic effects. It is almost expressed in all types of hematopoietic cells. The CXCR4 axis stimulates EGFR, MAPK, PI3K/AKT, Wnt/β-catenin, and NF-κB related pathways, which are involved in tumor development, survival, invasion, and homing. CXCR4/CXCL12 signaling is also involved in metastasis. Currently, CXCR4 has been detected in 23 different types of tumors, which is the most commonly expressed chemokine receptor in tumor cells and is associated with the prognosis of patients. The development of CXCR4 antagonists and the down-regulation of CXCR4 expression in cancer cells is of great significance for the treatment of related diseases.
Applications : Drug related studies
Review: Currently, CXCR4 has been detected in 23 different types of tumors and is the most commonly expressed chemokine receptor in tumor cells. It is one of the hot targets of drug research and also one of the key targets of our research. After comparing CXCR4 products from multiple manufacturers, we found that CUSABIO\'s CXCR4 product is stable and has good activity. In our ELISA experiment, the EC50 was measured to be 41.51-79.15 ng/ml, which can be used for subsequent research.
By Anonymous